PDF Report (1.8Mb)
View other formats
This is the first comprehensive national report on prostate cancer in Australia. It presents an overview of the condition and analysis of key summary measures including incidence, mortality and survival.
Health-care expenditure on prostate cancer was estimated to increase 23% between 2004–05 and 2008–09, to $349 million
Prostate cancer is the most commonly diagnosed cancer in Australia, with 21,808 new diagnoses in 2009
Prostate cancer is the fourth leading cause of mortality among Australian males, with 3,294 deaths in 2011
Indigenous males were less likely to be diagnosed with, but similarly likely to die from, prostate cancer
The effect of prostate cancer is wide reaching—affecting males diagnosed with the condition, their families and communities.
Prostate cancer in Australia is the first comprehensive national report on prostate cancer in Australia. It provides an overview of the condition, its risk factors, diagnosis and management, and key summary measures including incidence, mortality and survival. Comparisons over time and by age, selected population groups and international region are also presented.
There were 21,808 new cases of prostate cancer diagnosed in 2009. The age-standardised incidence of prostate cancer has increased over time, from 79 new cases per 100,000 males in 1982 to 194 per 100,000 in 2009. This increase is expected to continue, reaching 25,000 new cases per year in 2020, due to increases in the number of men presenting for testing, changes in diagnostic practices and the ageing of the population.
There were 3,294 deaths from prostate cancer recorded in 2011, making it the fourth leading cause of death among Australian males, behind coronary heart diseases, lung cancer and cerebrovascular diseases. The age-standardised mortality rate has decreased over time, from 34 deaths per 100,000 males in 1982 to 31 deaths per 100,000 in 2011. This decline is expected to continue, to 26 deaths per 100,000 males in 2020.
In 2006–2010, around 9 in 10 (92%) males diagnosed with prostate cancer survived 5 years from diagnosis. This is higher than for all cancers among males (65%), as well as other leading cancers among males, including melanoma of the skin (89%) and lung cancer (13%). Prostate cancer 5-year survival is high and has improved from 59% in 1986 to 90% in 2007.
Health-care expenditure on prostate cancer was estimated to be $349 million in 2008–09, an increase of 23% on expenditure in 2004–05. This increase in expenditure on prostate cancer corresponds with the increase in new cases of prostate cancer identified between 2002 and 2008.
Aboriginal and Torres Strait Islander males were less likely to be diagnosed with prostate cancer, but similarly likely to die from prostate cancer, compared with non-Indigenous males. Males living in Inner regional areas were more likely to be diagnosed with prostate cancer (186 new cases per 100,000 males) and those living in Remote/Very remote areas were less likely (150 per 100,000), compared with males living in all other regions.
The observed differences between these population groups could be due to variations in: rates of presenting for testing, population risk profiles and population age structures.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.